SCHEDULE: Janus Henderson Reports 7.3% Stake in Dyne Therapeutics

Janus Henderson Group Ltd. has disclosed a beneficial ownership of 7.3% of Dyne Therapeutics Inc.'s common stock as of June 30, 2026.

Summary

• Janus Henderson Group Ltd. has filed a Schedule 13G, indicating it beneficially owns 11,997,738 shares of Dyne Therapeutics Inc. common stock.
• This holding represents 7.3% of the total class of securities.
• The filing is an amendment (Amendment No. 7) and the event date requiring the filing is June 30, 2026.
• Janus Henderson Group Ltd. acts as the ultimate parent of several SEC-registered investment advisers and their foreign equivalents, referred to as Asset Managers.
• These Asset Managers may be deemed beneficial owners due to their investment and/or voting discretion over client assets (Managed Portfolios).
• However, the Asset Managers disclaim ownership rights to dividends and sale proceeds from these securities.
• No single Managed Portfolio owns more than five percent of Dyne Therapeutics Inc. common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing as neutral to slightly positive, indicating a significant but stable institutional holding without immediate implications for control or strategy changes.

Positives

• Significant institutional ownership by a reputable asset manager like Janus Henderson Group Ltd. can lend credibility and stability to the stock.
• The disclosure confirms continued institutional interest in Dyne Therapeutics.

Negatives

• The filing does not provide any new strategic information or financial performance data for Dyne Therapeutics itself, only the ownership stake.
• The disclaimer regarding dividends and sale proceeds means the direct benefit of ownership is with the underlying clients, not Janus Henderson Group Ltd. itself.

Risks

• Potential for future changes in Janus Henderson's stake, which could impact share price if significant buying or selling occurs.
• The disaggregation of ownership from ultimate parent Jupiter Topco LLC means that the full extent of related institutional holdings is not consolidated in this filing.

Future Outlook

This filing is primarily a disclosure of ownership and does not contain forward-looking statements or guidance regarding Dyne Therapeutics' future performance.

Management Comments

• In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Janus Henderson Group Ltd. It does not include securities, if any, beneficially owned by Janus Henderson Group Ltd.s ultimate parent Jupiter Topco LLC, the direct or indirect owners of Jupiter Topco LLC, or other persons that may be deemed under control of such owners. Any beneficial ownership by such persons has been disaggregated from that of Janus Henderson Group Ltd. in accordance with the release.
• The Asset Managers generally exercise investment and/or voting discretion on behalf of their clients which include investment companies, other investment advisers, institutional separate accounts and retail separate accounts (collectively referred to herein as Managed Portfolios).
• As a result of their exercise of investment and/or voting discretion on behalf of the Managed Portfolios, the Asset Managers may be deemed to be the beneficial owner of 11,997,738 common stock of Dyne Therapeutics, Inc.
• However, the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights.

Industry Context

StockSavvy.ai notes that significant institutional holdings, as disclosed in Schedule 13G filings, are common in the biotechnology sector. Such filings indicate that established investment firms are allocating capital to companies like Dyne Therapeutics, often based on their perceived potential in drug development and clinical trials.

Related Party Transactions

• Janus Henderson Group Ltd. disclaims beneficial ownership of dividends and sale proceeds from the securities held in the Managed Portfolios, as these rights belong to the clients (Managed Portfolios).

Stakeholder Impact

• Shareholders: The disclosure confirms a significant institutional investor's presence, which can be viewed positively for stock stability and potential future institutional interest.
• Clients of Janus Henderson (Managed Portfolios): These clients are the ultimate beneficiaries of the stock's performance, as the assets are held within their investment portfolios.

Next Steps

• Monitor future filings from Janus Henderson Group Ltd. for any changes in their stake.
• Observe Dyne Therapeutics' own SEC filings for strategic updates or financial performance reports.

Key Dates

Keywords

Dyne Therapeutics, Janus Henderson Group, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, Asset Manager